

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/706,567	11/12/2003	James L. Sackrison	DIA1001US 6918		
9561 7590 11/02/2005 EXAMINER					
•	WILES & O'CONNE	VENCI, DAVID J			
650 THIRD AVENUE SOUTH SUITE 600 MINNEAPOLIS, MN 55402			ART UNIT	PAPER NUMBER	
			1641		
			DATE MAILED: 11/02/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Advisory Action** Before the Filing of an Appeal Brief

Application No.	Applicant(s)	Applicant(s)		
10/706,567	SACKRISON ET AL.			
Examiner	Art Unit			
David J. Venci	1641	÷		

	David J. Venci	1641	•
The MAILING DATE of this communication appe	ars on the cover sheet with the	correspondence add	ress
THE REPLY FILED <u>September 7, 2005</u> FAILS TO PLACE THI	S APPLICATION IN CONDITION I	FOR ALLOWANCE.	
<ol> <li>The reply was filed after a final rejection, but prior to or o this application, applicant must timely file one of the follo places the application in condition for allowance; (2) a No (3) a Request for Continued Examination (RCE) in comp following time periods:</li> </ol>	owing replies: (1) an amendment, a otice of Appeal (with appeal fee) in	iffidavit, or other evidence with 37 (	ence, which CFR 41.31; or
a) The period for reply expires 3 months from the mailing date of	the final rejection.		
b) The period for reply expires on: (1) the mailing date of this Adv event, however, will the statutory period for reply expire later the Examiner Note: If box 1 is checked, check either box (a) or (b)	isory Action, or (2) the date set forth in th an SIX MONTHS from the mailing date o	f the final rejection.	
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f		INOT KEI ET WAROTTEE	5 W
Extensions of time may be obtained under 37 CFR 1.136(a). The date on been filed is the date for purposes of determining the period of extension a CFR 1.17(a) is calculated from: (1) the expiration date of the shortened stabove, if checked. Any reply received by the Office later than three month earned patent term adjustment. See 37 CFR 1.704(b).  NOTICE OF APPEAL	and the corresponding amount of the fee. atutory period for reply originally set in the	The appropriate extension final Office action; or (2)	on fee under 37 as set forth in (b)
2. The Notice of Appeal was filed on <u>September 7, 2005</u> . A of the date of filing the Notice of Appeal (37 CFR 41.37(a appeal. Since a Notice of Appeal has been filed, any replAMENDMENTS	a)), or any extension thereof (37 CF	R 41.37(e)), to avoid	dismissal of the
3. X The proposed amendment(s) filed after a final rejection,	but prior to the date of filing a brie	ef will not be entered	because
(a) They raise new issues that would require further co			
(b) They raise the issue of new matter (see NOTE below		,.	
(c) $oxtimes$ They are not deemed to place the application in be	tter form for appeal by materially re	educing or simplifying	the issues for
appeal; and/or			
(d) They present additional claims without canceling a	-	ejected claims.	
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1	` ***	l'	(DTOL COA)
4. The amendments are not in compliance with 37 CFR 1.		ompliant Amendmen	(PTOL-324).
5. Applicant's reply has overcome the following rejection(s			
<ol> <li>Newly proposed or amended claim(s) would be a the non-allowable claim(s).</li> </ol>	illowable if submitted in a separate	e, timely filed amendin	tent canceling
<ol> <li>For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro</li> </ol>	will not be entered, or b) worlded below or appended.	vill be entered and an	explanation of
The status of the claim(s) is (or will be) as follows: Claim(s) allowed: <u>none</u> .			
Claim(s) objected to: none.			-
Claim(s) rejected: <u>1-9 and 11-14</u> .			
Claim(s) withdrawn from consideration: <u>none</u> .			
AFFIDAVIT OR OTHER EVIDENCE			
B.  The affidavit or other evidence filed after a final action, because applicant failed to provide a showing of good ar and was not earlier presented. See 37 CFR 1.116(e).			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessal	overcome all rejections under appe	eal and/or appellant fa	ils to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER			
<ol> <li>The request for reconsideration has been considered by <u>See Continuation Sheet.</u></li> </ol>	ut does NOT place the application	in condition for allowa	ance because:
<ul><li>12.  Note the attached Information Disclosure Statement(s).</li><li>13.  Other:</li></ul>	(PTO/SB/08 or PTO-1449) Paper	No(s).	he.
See Continuation Sheet.  12. Note the attached Information Disclosure Statement(s).  13. Other:	SUP	LONG V. LE PRVISOPY PATENT E	c/r8/os EXAMINER
	. Т	edika day cente	1600

U.S. Patent and Trademark Office PTOL-303 (Rev. 7-05)

## Continuation Sheet (PTOL-303)

Application No.

Continuation of 3: Applicants' amendment raises new issues that may require additional consideration and/or search. Specifically, claim 1 is amended to add the step of "contacting the sample with an antibody". Such a step limitation was not previously considered and may raise new issues under Sections 102, 103 and/or 112 of Title 35 USC.

Examiner posits that, in general, a step of "contacting the sample with an antibody" is not an inherent feature of all immunoassays. For example, an immunoassay may involve a sample comprising an antibody to assay said antibody. In such an immunoassay, a step of "contacting the sample with an antibody" is not required.

Continuation of 11: Applicants' amendment raises new issues that may require additional consideration and/or search. Specifically, claim 1 is amended to add the step of "contacting the sample with an antibody". Such a step limitation was not previously considered and may raise new issues under Sections 102, 103 and/or 112 of Title 35 USC.

Examiner posits that, in general, a step of "contacting the sample with an antibody" is not an inherent feature of all immunoassays. For example, an immunoassay may involve a sample comprising an antibody to assay said antibody. In such an immunoassay, a step of "contacting the sample with an antibody" is not required.